CN103347537A - 抗叶酸受体α抗体糖型 - Google Patents

抗叶酸受体α抗体糖型 Download PDF

Info

Publication number
CN103347537A
CN103347537A CN2011800503838A CN201180050383A CN103347537A CN 103347537 A CN103347537 A CN 103347537A CN 2011800503838 A CN2011800503838 A CN 2011800503838A CN 201180050383 A CN201180050383 A CN 201180050383A CN 103347537 A CN103347537 A CN 103347537A
Authority
CN
China
Prior art keywords
amino acid
fra
acid sequence
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800503838A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·萨斯
N·尼古莱德斯
L·格拉索
E·鲁蒂埃
W·顾
J·扬
J·姚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of CN103347537A publication Critical patent/CN103347537A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2011800503838A 2010-10-20 2011-10-19 抗叶酸受体α抗体糖型 Pending CN103347537A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Publications (1)

Publication Number Publication Date
CN103347537A true CN103347537A (zh) 2013-10-09

Family

ID=45975873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800503838A Pending CN103347537A (zh) 2010-10-20 2011-10-19 抗叶酸受体α抗体糖型

Country Status (12)

Country Link
US (1) US20120164137A1 (https=)
EP (1) EP2629798A4 (https=)
JP (1) JP2014505012A (https=)
KR (1) KR20140032944A (https=)
CN (1) CN103347537A (https=)
AU (2) AU2011317088B2 (https=)
BR (1) BR112013009275A2 (https=)
CA (1) CA2815080A1 (https=)
IL (1) IL225579A0 (https=)
MX (1) MX2013004202A (https=)
RU (1) RU2013122843A (https=)
WO (1) WO2012054654A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118344485A (zh) * 2024-06-18 2024-07-16 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
US9512223B2 (en) * 2012-05-15 2016-12-06 Morphotek, Inc. Methods for treatment of gastric cancer
HUE049693T2 (hu) * 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
JP6224619B2 (ja) * 2012-12-07 2017-11-01 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374546A (zh) * 2005-12-16 2009-02-25 Ibc医药公司 基于多价免疫球蛋白的生物活性装配体
CN101374545A (zh) * 2005-04-15 2009-02-25 免疫基因公司 消除肿瘤中的异质或混合细胞群体
US20090274697A1 (en) * 2004-02-12 2009-11-05 Luigi Grasso Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261229A1 (en) * 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
PL1776384T3 (pl) * 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274697A1 (en) * 2004-02-12 2009-11-05 Luigi Grasso Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
CN101374545A (zh) * 2005-04-15 2009-02-25 免疫基因公司 消除肿瘤中的异质或混合细胞群体
CN101374546A (zh) * 2005-12-16 2009-02-25 Ibc医药公司 基于多价免疫球蛋白的生物活性装配体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118344485A (zh) * 2024-06-18 2024-07-16 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Also Published As

Publication number Publication date
JP2014505012A (ja) 2014-02-27
WO2012054654A2 (en) 2012-04-26
BR112013009275A2 (pt) 2017-06-20
IL225579A0 (en) 2013-06-27
AU2011317088A1 (en) 2013-05-02
AU2016202082A1 (en) 2016-04-28
US20120164137A1 (en) 2012-06-28
MX2013004202A (es) 2013-10-17
CA2815080A1 (en) 2012-04-26
EP2629798A2 (en) 2013-08-28
RU2013122843A (ru) 2014-11-27
WO2012054654A3 (en) 2012-08-02
AU2011317088B2 (en) 2016-01-21
KR20140032944A (ko) 2014-03-17
EP2629798A4 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CN103347537A (zh) 抗叶酸受体α抗体糖型
CN105452294B (zh) 癌的治疗和/或预防用药物组合物
ES2691794T3 (es) Anticuerpo anti-FOLR1
TW202120558A (zh) 新型抗ｃｌｄｎ１８．２抗體
JP7469305B2 (ja) 抗ｐｄ－１抗体およびその使用
JP2019526595A (ja) 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ
KR20230110523A (ko) 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
KR20200124701A (ko) 항―ｐｄ－１ 항체 및 그의 용도
TW202309088A (zh) 新的穩定抗ｖｉｓｔａ抗體
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
EP4671277A1 (en) Pharmaceutical Composition of the FAP/CD40 Binding Molecule and its Pharmaceutical Use
US20250270323A1 (en) Hhla2 binding agents with novel activity
DK2726508T3 (en) ANTIBODIES AGAINST ADP-RIBOSYL-CYCLASE-2
US20250059297A1 (en) Anti-her2/trop2 antibodies and uses thereof
EP4624492A1 (en) Anti-ccr8 antibody and use thereof
US20260028405A1 (en) Anti-cd16a antibodies and methods of use thereof
WO2023138677A1 (en) Novel anti-lag3 antibodies and derivative products
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
WO2022012559A1 (zh) 抗cldn-18.2抗体及其用途
WO2023072294A1 (en) Novel anti-lag3 antibodies
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
WO2025119322A1 (en) Gpc3 antibody-drug conjugates and use thereof
US20240238439A1 (en) Her3-binding antibody-drug conjugate
TW202523694A (zh) 抗muc16抗體及其用途
TW202542201A (zh) 抗psma軛合物及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131009